RxDoctor Payments Data

Tad Venn, MD

Geriatric Medicine · Columbia, SCNPI 1891810479

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Exact Sciences at 34.4% of the total.

$430in general payments, 2019–2025

Across 23 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$148
  • Abbott$95
  • Novartis$68
  • Dexcom, Inc.$43
  • Alnylam Pharmaceuticals Inc.$27
  • AstraZeneca$27
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$430 in reported general payments places this provider in the 70th percentile of 41 geriatric medicine providers in South Carolina.

See all geriatric medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$43,791
Medicare patients
191
Services billed
732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide126$212,179
JardianceEmpagliflozin77$89,269
FarxigaDapagliflozin Propanediol70$83,353
TrulicityDulaglutide49$78,625
EliquisApixaban76$75,691
OzempicSemaglutide50$66,459
JanuviaSitagliptin Phosphate46$50,102
XareltoRivaroxaban31$31,489
Tresiba Flextouch U-200Insulin Degludec22$27,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$25,175
LinzessLinaclotide29$21,872
Spiriva RespimatTiotropium Bromide32$20,383
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$14,605
Breo ElliptaFluticasone/Vilanterol15$13,657
Albuterol Sulfate HfaAlbuterol Sulfate274$12,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$27$93,64899 claims
Novo NordiskOzempic$23$66,45950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 41 geriatric medicine providers in South Carolina.

Other geriatric medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →